Form 4: Prime Medicine Officer Granted 140,000 Stock Options

Prime Medicine's SVP, Finance and Chief Accounting Officer, Carman Alenson, was granted 140,000 stock options with an exercise price of $3.34.

Summary

• Carman Alenson, SVP, Finance and Chief Accounting Officer of Prime Medicine, Inc. (PRME), was granted 140,000 stock options.
• The options have an exercise price of $3.34 per share.
• The grant date for these options was February 23, 2026.
• The options will vest in substantially equal monthly installments over 48 months (1/48th per month) starting from February 23, 2026, contingent on continued service.
• The options expire on February 23, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine executive compensation event, which is generally positive for aligning management incentives with shareholder interests, but it does not provide new operational or financial performance data.

Positives

• The grant of stock options to a key executive like the SVP, Finance and Chief Accounting Officer, aligns their interests with long-term shareholder value.
• The vesting schedule over 48 months encourages executive retention and sustained performance.

Risks

• The value of the stock options is dependent on Prime Medicine's stock price appreciating above the $3.34 exercise price.
• The options are subject to forfeiture if the reporting person's service terminates before full vesting.

Future Outlook

The stock option grant with a multi-year vesting schedule indicates an expectation of continued service from the executive and a long-term commitment to the company's performance.

Industry Context

StockSavvy.ai notes that equity grants, particularly stock options with multi-year vesting, are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries. This practice aims to incentivize long-term performance and align executive interests with shareholder value, a common strategy for retaining key talent in competitive sectors.

Comparison to Industry Standards

• The grant of 140,000 stock options to a Chief Accounting Officer is a common practice in biotech companies of similar market capitalization to Prime Medicine, Inc.
• A 4-year vesting schedule (48 months) is standard for executive equity grants across the U.S. market, comparable to practices at companies like Moderna (MRNA) or BioNTech (BNTX) for similar roles, though the specific number of options would vary based on company size and compensation philosophy.

Stakeholder Impact

• Shareholders: Potential positive impact through better alignment of executive incentives with long-term company performance. Dilution risk if options are exercised and new shares are issued, though this is standard for equity compensation.
• Employees: No direct impact on general employees, but reinforces the company's compensation structure for key executives.

Next Steps

• Continued vesting of the 140,000 stock options over the next 48 months, subject to Carman Alenson's continued service.
• Potential exercise of vested options by Carman Alenson at or after the exercise price of $3.34.

Key Dates

Recommendation

This Form 4 filing reports a standard executive stock option grant, which is a routine compensation event and does not provide new fundamental information about Prime Medicine's operational performance or financial health. While it aligns executive incentives, it does not warrant a change in investment recommendation based solely on this disclosure. Investors should continue to hold and monitor broader company developments.

Keywords

Prime Medicine, PRME, Stock Options, Insider Transaction, Form 4, Executive Compensation, Carman Alenson, Equity Grant